ABSI Stock — Absci Corporation: Cash, EV, Pipeline

Share price

$9.65

Market cap

$1,656.1M

Cash

$201.1M

Enterprise value

$1,455.0M

Balance sheet

Cash	$201.1M
Debt	$0.0M
Net cash	$201.1M
Enterprise value	$1,455.0M
Basic shares	157.5M shares
Fully diluted shares	208.1M shares
Fully diluted market cap	$2,008.6M
Cash per share	$1.28

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ABSI daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 12 - Sep 23	SAD IV Dose 1 - 150mg ABS201 IV Single Dose	Phase 1/2	Androgenetic Alopecia (AGA); Healthy Volunteers - Male and Female	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ABS-201

Phase 1 · Active Modality: antibody

Target PRLR (prolactin receptor)

Indications

pattern hair loss (PHL) (Phase 1)
endometriosis (Phase 2)

Catalysts

— Q4 2026
— H2 2027

Status note Anti-PRLR antibody with extended half-life. HEADLINE Phase 1/2a trial in PHL ongoing (interim Phase 1 data reported June 2026); Phase 2 trial in endometriosis anticipated to initiate Q4 2026.

ABS-202

Preclinical · Active Modality: antibody

Target PRLR (prolactin receptor)

Indications

undisclosed immunology and inflammation indication (Preclinical)

Status note Second novel anti-PRLR antibody program, designed via generative AI platform; indication undisclosed.

ABS-101

Stage not disclosed · Active Modality: antibody

Target TL1A

Indications

inflammatory bowel disease (IBD) (Stage not disclosed)

Status note Mentioned only in the 10-K competitive landscape section as a TL1A-targeting candidate; stage not stated in the filings reviewed.

ABS-301

Preclinical · Active

Indications

oncology (indication not specified) (Preclinical)

Status note Potential first-in-class oncology asset discovered through the company's reverse immunology platform; per 10-K business section.

ABS-501

Preclinical · Active

Target HER2

Indications

HER2-expressing cancers (indication not specified) (Preclinical)

Status note Potentially differentiated HER2 program; per 10-K business section.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SAD IV Dose 1 - 150mg ABS201 IV Single Dose
Lead indication	Androgenetic Alopecia (AGA)
Lead phase	Phase 1/2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07317544	Phase 1/2	Recruiting	Sponsor	Absci Pty Ltd.	—	Androgenetic Alopecia (AGA); Healthy Volunteers - Male and Female	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Absci Pty Ltd. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	2,134,803	no change	0.12%	2026-08-14
Ikarian Capital	353,772	+353,772	0.67%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ABSI — Absci Corporation

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders